Immunic
IMUX
54 hedge funds and large institutions have $54.5M invested in Immunic in 2016 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 21 increasing their positions, 11 reducing their positions, and 8 closing their positions.
155% more call options, than puts
Call options by funds: $423K | Put options by funds: $166K
91% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 11
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
4% more funds holding
Funds holding: 52 → 54 (+2)
37% less capital invested
Capital invested by funds: $86.7M → $54.5M (-$32.2M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$565K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$260K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$230K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$122K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
+$112K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.01M |
| 2 |
RIM
RS Investment Management
San Francisco,
California
|
-$1.33M |
| 3 |
PA
Perceptive Advisors
New York
|
-$271K |
| 4 |
Goldman Sachs
New York
|
-$187K |
| 5 |
MLICM
Metropolitan Life Insurance Company (MetLife)
New York
|
-$152K |
IMUX Hedge Fund Activity: Q2 2016 in Review
54 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Immunic (IMUX) for Q2 2016, worth a combined $54.5M — down 37% from $86.7M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new IMUX positions and 8 closed out — a net gain of 2 holders — while 21 added to existing stakes and 11 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $565K. The largest seller was Fidelity Investments, cutting an estimated $6.01M.
- 54 institutional investors held Immunic (IMUX) as of Q2 2016, up from 52 in Q1 2016.
- Funds reported $54.5M of Immunic stock for Q2 2016, down 37% quarter-over-quarter.
- 10 funds opened new Immunic positions in Q2 2016 and 8 closed out, a net change of +2 holders.
- The largest Immunic buyer in Q2 2016 was BlackRock Fund Advisors, an estimated $565K added.
- The largest Immunic seller in Q2 2016 was Fidelity Investments, an estimated $6.01M sold.
Based on aggregated 13F filings for Q2 2016.